STOCK TITAN

BIOLASE TO REPORT FOURTH QUARTER AND FULL YEAR 2022 RESULTS ON MARCH 28, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

LAKE FOREST, Calif., March 13, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release fourth quarter and full year 2022 financial and operating results on Tuesday, March 28, 2023, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and corporate developments.

To access the live call, dial 888-506-0062 (U.S.) or +1 973-528-0011 (International) and provide the following earnings code: 121864.

A live and archived webcast of the conference call will be accessible on the BIOLASE Investor Relations Page. In addition, a phone replay will be available approximately two hours following the end of the call, and it will remain available for one week. To access the call replay dial 877-481-4010 or +1 919-882-2331 (International) and enter replay passcode 47764.

About BIOLASE
BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine. BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately 302 patented and 28 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Contacts:
EVC Group, Inc. 
Michael Polyviou/Todd Kehrli 
(732) 232-6914 
mpolyviou@evcgroup.com; tkehrli@evcgroup.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biolase-to-report-fourth-quarter-and-full-year-2022-results-on-march-28-2023-301769761.html

SOURCE BIOLASE, Inc.

Biolase Inc

NASDAQ:BIOL

BIOL Rankings

BIOL Latest News

BIOL Stock Data

Dental Equipment and Supplies Manufacturing
Manufacturing
Link
Health Technology, Medical Specialties, Manufacturing, Dental Equipment and Supplies Manufacturing
US
Irvine

About BIOL

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.